TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
GNI Group ( (JP:2160) ) has shared an update.
GNI Group Ltd. reported its consolidated financial results for the third quarter of fiscal year 2025, showing a revenue increase of 12.6% year-on-year to 19,357 million yen. However, the company faced operating and pre-tax losses, with a notable decline in profit attributable to owners of the parent. Despite the revenue growth, the financial results indicate challenges in profitability, which may impact the company’s market positioning and stakeholder confidence.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2291.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs. The company is listed on the Tokyo Stock Exchange under stock code 2160.
Average Trading Volume: 1,100,268
Technical Sentiment Signal: Hold
Current Market Cap: Yen141.3B
For an in-depth examination of 2160 stock, go to TipRanks’ Overview page.